The intense need for in-depth understanding of the “Atopic Dermatitis Market -Forecast to 2023″ coupled with its high growth potential necessitated the development of this report by Market Research Future. The report specifically focuses on the key industry development trends and forces that shapes the market, but not limited to only commercial nature, but which encompasses a broad range such as social, technological and others. The global atopic dermatitis market is expected to grow at a CAGR of 8.2 % during the forecast period 2017-2023.
MarketResearchFuture.com adds “Atopic Dermatitis Market -2018 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2023” reports to its database.
The Americas dominate the global atopic dermatitis market owing to the presence of huge patient with skin diseases and infectious disorders, such as staphylococcal and streptococcal bacterial skin infections. Furthermore high healthcare spending, and increasing government support for research & development fuel the market growth.
Europe holds the second largest share of the global atopic dermatitis market as result of increasing focus of various government agencies on the treatment of allergic diseases. Moreover, the growing public awareness about atopic dermatitis is likely to boost the European market.
Asia Pacific is the fastest growing atopic dermatitis market across the globe. Moreover, rapidly developing economy, increasing healthcare expenditure, and the government’s initiatives for research & development is projected to drive the market in China and India over the forecasted period.
The Middle East and Africa h
The Americas dominate the global atopic dermatitis market owing to well-developed technology, increasing patient with low quantity of protein filaggrin, increasing prevalence atopic disorder, high healthcare spending, and increasing government support for research & development. Furthermore, increased R&D activities and the concentration of major companies have fuelled the growth of the market in this region. Rising in the adoption of skin irritants such as soaps, detergents, perfumes, cosmetics and even water may inflame the skin.
On the other hand, in the Middle East and Africa, blood disorders have become a huge problem due to limited screening, ignorance of diseases, and poor access to treatment.
Some of key the players in the market are Astellas Pharma Inc. (Japan), Sanofi S.A. (France), Regeneron Pharmaceuticals, Inc. (U.S.), Valeant Pharmaceuticals International, Inc (Canada), Anacor Pharmaceuticals Inc. (U.S.), Novartis International AG (Switzerland), Bristol-Myers Squibb (U.S.), Meda Pharmaceuticals (U.S.), Pfizer Inc. (U.S.), Galderma S.A. (Switzerland), Allergan Plc. (Republic of Ireland)
TRY FREE SAMPLE REPORT @ https://www.marketresearchfuture.com/sample_request/1610 .
Atopic dermatitis affects a large percentage of the world’s population. The skin of a patient with atopic dermatitis becomes dry, red, flaky and very itchy. Although atopic dermatitis can occur at any age, but mostly it affects infants and young children. Occasionally, it may persist in adults as well. Some patients tend to have a protracted course with ups and downs. Mostly, there are periods of time when the disease gets worse, known as exacerbations or flares, which is followed by periods when the skin improves or clears up entirely, called remissions.
Increasing prevalence of skin irritants such as soaps, detergents, perfumes, cosmetics and even water may produce inflammation that may cause the skin to become inflamed. Additionally rising demand for better treatment, increasing investment in biotechnology and pharmaceutical industries for R&D, and availability of funds drive the growth of the market. Moreover, increasing government support for research & development and rapidly developing technology is expected to fuel the market growth during the forecast period. However, high cost of the treatment may slow the market growth during the period 2017-2023.
According to a report published by the National Center for Biotechnology Information, in 2015, atopic dermatitis was recorded to affect around 20% of infants & children and 3% of adults globally
A research study published in the National Eczema Association, in 2016, shows that around 9.6 million children under the age of 18years, which is 13% of U.S. population, have atopic dermatitis. Additionally, in 2016, the United States spend around $314 million on health system to treat atopic dermatitis patients.
However, availability of expensive treatment and poor reimbursement policies in the developing regions of the world are some of the factors, which may hamper the market growth during the forecast period.
- Pharmaceutical Companies
- Medical Devices Companies
- Research and Development (R&D) Companies
- Government Research Institute
- Medical Research Laboratories
- Academic Medical Institutes and Universities
The global atopic dermatitis market is segmented on the basis of types, by application, and by end user. On the basis of the type, it is segmented into hormone, Erythropoietin, Monoclonal antibodies, Interferon, Calcitonin, and others. On the basis of the application, it is segmented into cancer, blood disorders, chronic diseases, infectious diseases, and others. On the basis of end user, it is segmented into hospitals, clinics, and research centers.
AVAIL AMAZING DISCOUNT ON REPORT @ https://www.marketresearchfuture.com/check-discount/1610 .
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.